| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2883374 | The Annals of Thoracic Surgery | 2006 | 6 Pages |
Abstract
Amiodarone prophylaxis reduced the prevalence and duration of POAF. Baseline risk for POAF was a major determinant of the overall cost-effectiveness of AMP. The greatest cost savings with AMP was seen in patients at an elevated risk for POAF. These findings suggest the need for risk stratification when prescribing AMP.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Brian J. PharmD, Erin A. PharmD, MS, Patricia A. PharmD, Dennis W. PhD, Michael E. MD, Jeffrey B. MD, Gregory F. MD, William A. MD,